Cuorips Inc. (4894) Cash flow

Market cap
¥57B
P/E ratio
-58.6x
Qualips develops regenerative medicine treatments using human iPS cells, specializing in cardiac muscle cell sheets for severe heart failure patients.
2021/032022/032023/032024/032025/03
Depreciation & amortization7493797077
Cash from operations -283-221-402-451-813
Capital expenditures-668-29-5-24-80
Cash from investing -670-28-9-35-120
Repurchases of common stock----0-1
Cash from financing 3,76749113,125145
Free cash flow
FCF margin (%)
AI Chat